So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

The company reported a 48% year-on-year (y-o-y) jump in its consolidated net profit to ₹1,571 crore in October-December, while its total revenue from operations rose 8% to ₹7,073 crore. Analysts ...

Cipla share price will remain in focus after the United States Food and Drug Administration (USFDA) has classified the ...

That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...

India's Cipla beats Q3 profit view as strong domestic ... joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. India's Dr Reddy's Q2 profit drops on acquisition ...

During the year, the Company issued and allotted 2,16,469 equity shares of Rs. 2/- each to its employees under the Employee Stock Option Scheme 2013-A and the Cipla Employee StockAppreciation ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024.

Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the Company’s manufacturing facility in Virgonagar, Bengaluru, India ...

Cipla, one of India's largest drugmaker by sales, reported a bigger-than-expected third-quarter profit on Tuesday, helped by strong demand, especially in the key North American market. The company's ...

Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...